Cardiotoxicity of Non-Cardiovascular Drugs (PDF)

Some drugs which are not aimed at treating heart disease have
nevertheless been found to have profound effects on heart muscle.
Cardiotoxicity is one of the major forms of toxicity seen in drugs
and it accounts for most drug recalls and delays experienced in
regulatory approvals.In recent years a number of non-cardiac
blockbuster drugs such as terfenadine have been withdrawn from
major markets because of cardiotoxicity concerns, while other drugs
have either been withdrawn prior to marketing or required labelling
changes that significantly restricted their use.

In Cardiotoxicity of Non-Cardiovascular Drugs
international experts describe the molecular mechanisms and
clinical read-outs of cardiac events induced by a broad variety of
noncardiovascular drugs. Particular emphasis is paid to the
preclinical screening of drug cardiotoxicity. Topics include:

* metabolic targets of cardiotoxicity

* regulatory aspects

* translating molecular mechanisms into clinical trials

* structure-activity relationships in arrhythmias by
antihistamines and psychoactive drugs

* cardiovascular toxicity of antitumor drugs

* cardiovascular toxicities of non-steroidal anti-inflammatory
drugs

* cardiovascular toxicities of antiretroviral therapies

Cardiotoxicity of Non-Cardiovascular Drugs is an
essential guide to this important area of drug development. It will
find a place on the bookshelves of researchers, regulators and
students in medicinal chemistry, drug development, pharmacology,
pharmacy and cardiovascular disease.